These analyses led us to hypothesize that the response to RSK and PLK1 inhibitors is defined by mitochondria, which is in line with the central role of these organelles in tumor progression and therapeutic resistance in melanoma (reviewed in Kumar et al [2021] and Du et al [2023]). This evidence concerns the gene PLK1 and neoplasm.